<unk> , sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.<unk>  has advanced to several Phase III clinical trials. The January 2014 results of the first trials were disappointing, with a failure to meet the study goals. Additional Phase III trials are ongoing. In 2017, results of a trial comparing<unk>  to gefitinib for NSCLC (driven by mutated EGFR) were announced.<unk>  was approved for medical use in the United States in September 2018, in Japan in 2019, and in the European Union in 2019, for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation.
Dacomitinib
Upadacitinib
Abrocitinib
Baricitinib
Erdafitinib
Axitinib
Delgocitinib
Ceritinib